Technical Analysis for REGN - Regeneron Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 385.94 0.10% 0.37
REGN closed up 0.1 percent on Friday, January 17, 2020, on 1.2 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: Feb 6
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical REGN trend table...

Date Alert Name Type % Chg
Stochastic Sell Signal Bearish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
NR7 Range Contraction 0.00%
Upper Bollinger Band Walk Strength 0.00%
Inside Day Range Contraction 0.00%
Bearish Engulfing Bearish 0.10%
Slingshot Bullish Bullish Swing Setup 0.10%
Upper Bollinger Band Walk Strength 0.10%
Overbought Stochastic Strength 0.10%
Upper Bollinger Band Touch Strength 0.10%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company offers EYLEA injection for the treatment of neovascular age-related macular degeneration and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its product candidates in clinical development stage consist of EYLEA for the treatment of ophthalmologic diseases; and ZALTRAP for oncology. The company's earlier stage clinical programs include various human monoclonal antibodies, such as REGN88 for rheumatoid arthritis; REGN727 for low-density lipoprotein cholesterol reduction; REGN668 for atopic dermatitis and allergic asthma; REGN421, REGN910, and REGN1400 for oncology; REGN475 for the treatment of pain; REGN846 for atopic dermatitis; and REGN1500, REGN1033, and REGN1154. It also conducts preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company distributes its products through third party service providers. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA outside the United States. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Medicine Biotechnology Health Biopharmaceutical Pain Immunology Infectious Diseases Antibodies Monoclonal Antibodies Inflammation Disorders Rheumatoid Arthritis Cardiovascular Diseases Atopic Dermatitis Macular Edema Sanofi Breakthrough Therapy Allergic Asthma Immune Diseases Metastatic Colorectal Cancer Regeneron

Is REGN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 442.0
52 Week Low 271.37
Average Volume 714,290
200-Day Moving Average 323.89
50-Day Moving Average 366.14
20-Day Moving Average 377.98
10-Day Moving Average 382.10
Average True Range 7.74
ADX 22.79
+DI 27.45
-DI 17.96
Chandelier Exit (Long, 3 ATRs ) 373.24
Chandelier Exit (Short, 3 ATRs ) 386.37
Upper Bollinger Band 389.90
Lower Bollinger Band 366.06
Percent B (%b) 0.83
BandWidth 6.31
MACD Line 6.22
MACD Signal Line 6.08
MACD Histogram 0.1422
Fundamentals Value
Market Cap 40.92 Billion
Num Shares 106 Million
EPS 9.97
Price-to-Earnings (P/E) Ratio 38.71
Price-to-Sales 8.43
Price-to-Book 7.99
PEG Ratio 1.55
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 392.05
Resistance 3 (R3) 391.59 389.09 391.03
Resistance 2 (R2) 389.09 387.54 389.32 390.69
Resistance 1 (R1) 387.52 386.58 386.27 387.98 390.35
Pivot Point 385.02 385.02 384.40 385.25 385.02
Support 1 (S1) 383.45 383.47 382.20 383.91 381.53
Support 2 (S2) 380.95 382.51 381.18 381.19
Support 3 (S3) 379.38 380.95 380.85
Support 4 (S4) 379.84